News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Taisho Pharmaceutical And Eli Lilly and Company (LLY) Terminate A License Agreement For Taisho's Potential New Drug For Treatment Of Type 2 Diabetes


8/7/2006 10:37:41 AM

Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) and Eli Lilly and Company [Headquarter: Indianapolis, Indiana, USA, President and COO: John Lechleiter, Ph.D.] (hereinafter, Lilly) have terminated a license agreement for potential new drug, TS-021, an inhibitor of dipeptidyl peptidase-IV (DPP-IV) for the treatment of type 2 diabetes originated by Taisho (Phase I clinical trial in Japan and USA). The decision was made by the fact that pre-clinical study results did not meet certain criteria set by Lilly.

>>> Discuss This Story


Read at Reuters
Read at Company Press Release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES